Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation (UPSAT)

2 de junio de 2022 actualizado por: Johns Hopkins University

UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)

COVID-19 is a respiratory illness caused by SARS-CoV-2 with a range of symptoms from mild, self-limiting respiratory tract infections to severe progressive pneumonia, multiorgan dysfunction and death. A portion of individuals with COVID-19 experience life-threatening hypoxia requiring supplemental oxygen and mechanical ventilation. Management of hypoxia in this population is complicated by contraindication of non-invasive ventilation and limitations in access to mechanical ventilation and critical care staff given the clinical burden of disease. Positional therapy is readily deployable and may ultimately be used to treat COVID-19 related respiratory failure in resources limited settings; and, it has been demonstrated to improve oxygenation and is easy to implement in the clinical setting.

The overall goal of this randomized controlled trial is to establish the feasibility of performing a randomized trial using a simple, minimally invasive positional therapy approach to improve hypoxia and reduce progression to mechanical ventilation. The objectives are to examine the effectiveness and feasibility of maintaining an inclined position in patients with confirmed or suspected COVID-19 associated hypoxemic respiratory failure. The investigators hypothesize that (1) oxyhemoglobin saturation will improve with therapy, (2) participants will tolerate and adhere to the intervention, and that (3) participants who adhere to positional therapy will have reduced rates of mechanical ventilation at 72 hours. If successful, this feasibility trial will demonstrate that a simple, readily deployed nocturnal postural maneuver is well tolerated and reverses underlying defects in ventilation and oxygenation due to COVID-19. It will also inform the design of a pivotal Phase III trial with estimates of sample sizes for clinically relevant outcomes.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

Study Design: The investigators will conduct a pilot study to examine the acute effects of inclined posture on oxyhemoglobin saturation and the feasibility of conducting randomized controlled clinical trial among patients with confirmed or suspected COVID-19-associated hypoxia.

In a subgroup of participants, the investigators will examine the acute effect of postural therapy (15-degree incline on hospital beds) on oxyhemoglobin saturation among hypoxic patients to establish a biologic response. The investigators will enroll a subset of participants (n=16) who will lie supine on hospital beds, which will be placed in the horizontal (flat) or 15-degree inclined (reverse Trendelenberg) orientation in random order. During this time, the investigators will continuous record pulse oximetry, pulse rate and variations in peripheral arterial tone with WatchPAT one devices. Subjects will be visually monitored for work of breathing during this time. If work of breathing becomes excessive, as defined as a sustain respiratory rate of >25 and an increase of >5 breaths per minute from baseline, or oxygenation decreases below 88% for > 30 seconds in the inclined position, then maneuvers will be stopped. If the patient meets these criteria in the flat position, then the investigators sit the patient upright, and allow breathing to return to baseline before examining responses in the inclined position.

The investigators will randomize participants to have beds placed in 15-degree incline or usual care (ad-lib positioning) for 72 hours. During the first night in a subgroup of participants, the investigators will record oxygenation, sleep wake state and markers of sympathetic activity with WatchPAT One devices, which can obtain cardiopulmonary parameters with high temporal resolution. The investigators will obtain vital signs from the data warehouse, which archives telemetry data with a maximum sampling frequency of 1 minute. The investigators will record adherence with continuous accelerometry sensors placed on the bed rails and on the anterolateral surface of participants' chests to measure bed and participants' positions, respectively. Aside from position, participants will receive usual treatment for COVID-19.

The investigators will enroll in 3 phases. At the end of each phase, the investigators will assess for completion of milestones for proceeding to the subsequent phase, as detailed below:

  1. Pilot Study: The investigators will pilot the study in 16 participants to obtain critical information on logistics of conducting the trial including performance of recording instruments in a biocontainment environment, to examine the feasibility of the intervention, perform preliminary safety evaluations to ascertain potential harm and to determine whether the intervention results in a meaningful difference in body position.
  2. Phase II RCT: If inclined therapy results in a difference in body position and no significant safety issues were detected, the investigators will conduct a phase II randomized-controlled trial (RCT) in 70 participants (see sample size calculation below) to estimate the effect size of inclined position on rates of intubation and determine sample size for a Phase III trial.

Randomization will be occur in both phases and will be stratified by study phase and study site.

Tipo de estudio

Intervencionista

Inscripción (Actual)

7

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins Hospital
      • Baltimore, Maryland, Estados Unidos, 21224
        • Johns Hopkins Bayview Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • COVID-19 positive
  • Pneumonia defined as hospitalization for acute (< 7 days) onset of symptoms (cough, sputum production, or dyspnea).
  • Hypoxemia defined as ≥ 2 L/min oxygen

Exclusion Criteria:

  • Intubation
  • Inability to lie supine

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Postural Positioning
Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
Sin intervención: Standard Care
Participants in this group will have beds managed per standard nursing protocol.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Mechanical Ventilation
Periodo de tiempo: 72 hours
Number of participants needing mechanical ventilation over total number of participants per arm.
72 hours

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with supplemental oxygen requirements
Periodo de tiempo: 72 hours
Number of participants with supplemental oxygen requirements.
72 hours
Mean oxyhemoglobin saturation
Periodo de tiempo: At 24, 48 and 72 hours
Mean oxyhemoglobin saturation (percentage) measured over a 24-hour period.
At 24, 48 and 72 hours
Mean Nocturnal Oxyhemoglobin Saturation
Periodo de tiempo: Measured between 10pm and 6am daily, up to 72 hours
Mean oxyhemoglobin saturation (percentage) measured over an 8-hour period (between 10pm and 6am).
Measured between 10pm and 6am daily, up to 72 hours
Heart Rate
Periodo de tiempo: At 10, 24, 48 and 72 hours
Heart Rate (beats per minute) on Routine Vital Sign Assessment.
At 10, 24, 48 and 72 hours
Respiratory Rate
Periodo de tiempo: At 10, 24, 48 and 72 hours
Respiratory Rate (cycles per minute) on Routine Vital Sign Assessment.
At 10, 24, 48 and 72 hours
Percentage of time in the assigned position
Periodo de tiempo: 72 hours
Percentage of time participants stay in the assigned position will be used to determine adherence.
72 hours

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Acute change in oxyhemoglobin saturation
Periodo de tiempo: During the final 7 minutes at each position, up to 72 hours
Mean oxyhemoglobin saturation (percentage) during final 7 minutes in a position.
During the final 7 minutes at each position, up to 72 hours

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Luu Pham, MD, Johns Hopkins University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de mayo de 2020

Finalización primaria (Actual)

1 de mayo de 2022

Finalización del estudio (Actual)

1 de mayo de 2022

Fechas de registro del estudio

Enviado por primera vez

10 de abril de 2020

Primero enviado que cumplió con los criterios de control de calidad

10 de abril de 2020

Publicado por primera vez (Actual)

14 de abril de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de junio de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

2 de junio de 2022

Última verificación

1 de junio de 2022

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB00246834

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Access to IPD on reasonable request

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre COVID-19

Ensayos clínicos sobre Postural Positioning

3
Suscribir